Gilead director granted RSUs and stock options

Gilead Sciences director Sandra Horning reported new equity compensation awards.

Rhea-AI Filing Summary

Gilead Sciences director Sandra Horning reported new equity compensation awards. She received 1,146 restricted stock units under the Gilead Sciences, Inc. 2022 Equity Incentive Plan, with each RSU representing one share of common stock and vesting immediately on April 30, 2026.

She was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, which vested 100% on April 30, 2026 and expires on April 30, 2036. Following these awards, she directly holds 6,293 shares of Gilead common stock.

Insider Trade Summary

Grant/Award: 6,030 shares

Grant/Award 2 txns

Insider Horning Sandra

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified Stock Option (Right to Buy)	4,884	$0.00	$0.00
Grant/Award	Common Stock	1,146	$0.00	$0.00

Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 4,884 contracts (Direct); Common Stock — 6,293 shares (Direct)

Footnotes (2)

1. F1. Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.
2. F2. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Key Figures

RSUs granted: 1,146 RSUs Stock options granted: 4,884 options Option exercise price: $130.84 per share +2 more

5 metrics

RSUs granted 1,146 RSUs Restricted stock units granted April 30, 2026; vested immediately

Stock options granted 4,884 options Non-qualified stock option granted April 30, 2026

Option exercise price $130.84 per share Exercise price for 4,884 non-qualified stock options

Option expiration April 30, 2036 Expiration date of non-qualified stock option

Shares held after grant 6,293 shares Common shares directly owned following April 30, 2026 transactions

Key Terms

restricted stock units ("RSUs"), Non-qualified Stock Option (Right to Buy), 2022 Equity Incentive Plan

3 terms

restricted stock units ("RSUs") financial

"Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Non-qualified Stock Option (Right to Buy) financial

"Security title is listed as Non-qualified Stock Option (Right to Buy) with 4,884 underlying shares."

2022 Equity Incentive Plan financial

"RSUs granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Gilead Sciences (GILD) report for Sandra Horning?

Gilead reported that director Sandra Horning received equity awards, including 1,146 RSUs and 4,884 stock options. These awards are part of her compensation and were granted under the company’s equity incentive plan, with all units and options vesting immediately on April 30, 2026.

How many RSUs did Sandra Horning receive from Gilead Sciences (GILD)?

Sandra Horning received 1,146 restricted stock units (RSUs) from Gilead Sciences. Each RSU represents the contingent right to receive one share of common stock, and all of these RSUs vested immediately on the grant date of April 30, 2026, making them fully earned that day.

What stock options were granted to Sandra Horning by Gilead Sciences (GILD)?

Sandra Horning was granted a non-qualified stock option for 4,884 shares of Gilead common stock at an exercise price of $130.84 per share. According to the filing, 100% of these option shares vested immediately on April 30, 2026 and the option expires on April 30, 2036.

What are Sandra Horning’s Gilead (GILD) share holdings after this Form 4?

After these transactions, Sandra Horning directly holds 6,293 shares of Gilead common stock. This total reflects the impact of the 1,146 RSUs that vested immediately. The reported options are separate derivative securities that can be exercised for additional shares in the future.

Under which plan were Sandra Horning’s new Gilead (GILD) equity awards granted?

The 1,146 RSUs granted to Sandra Horning were issued under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. The filing states that each RSU equals one share of common stock and that these RSUs vested in full immediately on the April 30, 2026 grant date.

When do Sandra Horning’s Gilead (GILD) stock options expire?

Sandra Horning’s non-qualified stock option for 4,884 shares expires on April 30, 2036. The filing notes that 100% of the shares subject to this option vested immediately on April 30, 2026, leaving the option fully exercisable until its expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horning Sandra

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	04/30/2026		A		1,146	A	$0	6,293	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified Stock Option (Right to Buy)	$130.84	04/30/2026		A		4,884		(2)	04/30/2036	Common Stock	4,884	$0	4,884	D

Explanation of Responses:

1. Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

2. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Remarks:

	/s/ Amy Kim by Power of Attorney for Sandra J. Horning	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)